首页 > 最新文献

Surgical Oncology-Oxford最新文献

英文 中文
Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer 术前和术后循环肿瘤 DNA (ctDNA) 与 PIK3CA 基因突变与非转移性乳腺癌患者复发风险的关系
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-03-05 DOI: 10.1016/j.suronc.2024.102060
Fara Hassan , Jiang Huai Wang , Donal Peter O'Leary , Mark Corrigan , Henry Paul Redmond

Background

Circulating tumour DNA (ctDNA), contains tumour-specific gene mutation in blood circulation and could aid in postoperative risk stratification of non-metastatic breast cancer. In this study, we investigated the feasibility of detecting PIK3CA gene mutations in ctDNA in the preoperative (preop) and postoperative period (postop), and its prognostic significance in patients with breast cancer.

Methods

A cohort of patients with breast cancer undergoing curative surgery with available blood samples preoperatively and postoperatively (Post op) at either Post op time period; week 1–2, week 3–4 or weeks 5–12 were enrolled. PIK3CA gene mutations at exons 9 and 20 were detected in ctDNA with High resolution melting (HRM) PCR and Allele specific fluorescence probe-based PCR.

Results

A total of 62 patients (age, median (IQR), 51.50 (45.0–65.0) years), with a median follow-up of 90 months (interquartile range (IQR),60–120 months) were enrolled. In total, 25 (40.3%) and 22 (35%) patients with breast cancer had detectable PIK3CA gene mutations in ctDNA in preoperative and postoperative period, respectively. PIK3CA gene mutations in ctDNA in postoperative period (hazard ratio (H.R: 18.05, p = 0.001) were a negative prognostic factor for recurrencefree survival (RFS) and overall survival (OS) (H.R: 11.9, p = 0.01) in patients with breast cancer. Subgroup analysis of ctDNA indicate that positive ctDNA in both preoperative/postoperative period and post op period only were found to have prognostic effect on RFS and OS (RFS; p < 0.0001, O·S; p = 0.0007). Moreover, ctDNA-based detection preceded clinical detection of recurrence in patients with an average lead time of 12 months (IQR:20–28.5 months) across all the breast cancer subtypes.

Conclusion

We highlighted the prognostic ability of ctDNA in patients with breast cancer in perioperative period. However, future prospective studies are needed to assess the utility of ctDNA in clinical practice

循环肿瘤 DNA(ctDNA)在血液循环中含有肿瘤特异性基因突变,有助于对非转移性乳腺癌进行术后风险分层。在这项研究中,我们探讨了在乳腺癌患者术前(preop)和术后(postop)检测ctDNA中PIK3CA基因突变的可行性及其预后意义。一组接受根治性手术的乳腺癌患者在术前和术后(PO)的任一时间点(PO 第 1-2 周、PO 第 3-4 周和 PO 第 5-12 周)均可获得血液样本。采用高分辨熔融(HRM)PCR 和基于等位基因特异性荧光探针的 PCR 技术检测ctDNA 中 PIK3CA 基因第 9 和 20 号外显子的突变。共纳入 62 名患者(年龄中位数(IQR)为 51.50(45.0-65.0)岁),中位随访时间为 90 个月(四分位数间距(IQR)为 60-120 个月)。共有25名(40.3%)和22名(35%)乳腺癌患者在术前和术后的ctDNA中分别检测到了PIK3CA突变。术后ctDNA中的PIK3CA突变(危险比(H.R:18.05,P = 0.001)是乳腺癌患者无复发生存期(RFS)和总生存期(O-S)的负预后因素(H.R:11.9,P = 0.01)。ctDNA亚组分析表明,术前/术后ctDNA阳性和仅术后ctDNA阳性对RFS和O-S有预后影响(RFS:p < 0.0001,O-S:p = 0.0007)。此外,在所有乳腺癌亚型中,基于ctDNA的检测先于临床检测出患者的复发,平均提前时间为12.00个月(IQR:20-28.5个月)。我们强调了ctDNA对围术期乳腺癌患者的预后能力。不过,未来还需要进行前瞻性研究,以评估ctDNA在乳腺癌中的应用。
{"title":"Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer","authors":"Fara Hassan ,&nbsp;Jiang Huai Wang ,&nbsp;Donal Peter O'Leary ,&nbsp;Mark Corrigan ,&nbsp;Henry Paul Redmond","doi":"10.1016/j.suronc.2024.102060","DOIUrl":"10.1016/j.suronc.2024.102060","url":null,"abstract":"<div><h3>Background</h3><p>Circulating tumour DNA (ctDNA), contains tumour-specific gene mutation in blood circulation and could aid in postoperative risk stratification of non-metastatic breast cancer. In this study, we investigated the feasibility of detecting PIK3CA gene mutations in ctDNA in the preoperative (preop) and postoperative period (postop), and its prognostic significance in patients with breast cancer.</p></div><div><h3>Methods</h3><p>A cohort of patients with breast cancer undergoing curative surgery with available blood samples preoperatively and postoperatively (Post op) at either Post op time period; week 1–2, week 3–4 or weeks 5–12 were enrolled. PIK3CA gene mutations at exons 9 and 20 were detected in ctDNA with High resolution melting (HRM) PCR and Allele specific fluorescence probe-based PCR.</p></div><div><h3>Results</h3><p>A total of 62 patients (age, median (IQR), 51.50 (45.0–65.0) years)<strong>,</strong> with a median follow-up of 90 months (interquartile range (IQR),60–120 months) were enrolled. In total, 25 (40.3%) and 22 (35%) patients with breast cancer had detectable PIK3CA gene mutations in ctDNA in preoperative and postoperative period, respectively. PIK3CA gene mutations in ctDNA in postoperative period (hazard ratio (H.R: 18.05, p = 0.001) were a negative prognostic factor for recurrencefree survival (RFS) and overall survival (OS) (H.R: 11.9, p = 0.01) in patients with breast cancer. Subgroup analysis of ctDNA indicate that positive ctDNA in both preoperative/postoperative period and post op period only were found to have prognostic effect on RFS and OS (RFS; p &lt; 0.0001, O·S; p = 0.0007). Moreover, ctDNA-based detection preceded clinical detection of recurrence in patients with an average lead time of 12 months (IQR:20–28.5 months) across all the breast cancer subtypes.</p></div><div><h3>Conclusion</h3><p>We highlighted the prognostic ability of ctDNA in patients with breast cancer in perioperative period. However, future prospective studies are needed to assess the utility of ctDNA in clinical practice</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"54 ","pages":"Article 102060"},"PeriodicalIF":2.3,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960740424000288/pdfft?md5=2491c84290d9ba4a7997c318b52cfb73&pid=1-s2.0-S0960740424000288-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140071872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The significance of resection margins on R0 results in intrahepatic cholangiocarcinoma 切除边缘对肝内胆管癌 R0 结果的影响
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-29 DOI: 10.1016/j.suronc.2024.102058
B.O. Stüben , S. Ahmadi , F.H. Saner , J. Li , J.P. Neuhaus , J.W. Treckmann , D.P. Hoyer

Background

Intrahepatic cholangiocarcinoma is the second most common primary liver cancer after hepatocellular carcinoma with an increasing incidence worldwide. Surgical resection is still the only potential cure, and survival rates are dismal due to disease relapse after resection and/or metastatic disease. Positive resection margins are associated with recurrence, with conflicting studies regarding the benefits of wide resection margins to reduce recurrence rates.

Methods

126 patients with an R0 resection treated with hepatic surgery for intrahepatic cholangiocarcinoma at the Surgical Department at the Medical University Centre Essen, Germany were identified in a database and retrospectively analysed. Patients were grouped into three groups according to margin width, <1 mm (very narrow margin width) 1–5 mm (narrow margin width) and >5 mm (wide margin width). Epidemiological as well as perioperative data was analysed, and a univariate analysis as well as Kaplan-Meier plots carried out to investigate recurrence-free and overall survival.

Results

Wider resection margins did not lead to better recurrence-free survival.

A wider resection margin >5 mm was not significantly associated with improved overall survival.

Positive lymph nodes (HR 2.50, 95% CI 1.11–5.61, p=0.027) and non-anatomic resections (HR 2.06, 95% CI 1.13–3.75, p=0.019) are significantly associated with poorer overall survival. Regarding recurrence-free survival, V2 vascular invasion was the only risk factor statistically significantly associated with poorer recurrence-free survival (HR 8.83, 95% CI 0.85–2.83, p=0.005).

Conclusion

Resection margins did not have a significant impact on disease free survival or overall survival following hepatic resection for intrahepatic cholangiocarcinoma. Non-anatomical resections, lymph node and vascular invasion all significantly impacted oncological outcomes.

背景肝内胆管癌是仅次于肝细胞癌的第二大常见原发性肝癌,在全球的发病率不断上升。手术切除仍是唯一可能治愈的方法,但由于切除后复发和/或转移性疾病,生存率很低。切除边缘阳性与复发有关,关于宽切除边缘对降低复发率的益处,研究结果相互矛盾。研究方法:在数据库中识别了德国埃森医科大学中心外科部门肝内胆管癌 R0 切除的 126 例患者,并进行了回顾性分析。根据边缘宽度将患者分为三组:1 毫米(边缘宽度很窄)、1-5 毫米(边缘宽度很窄)和 5 毫米(边缘宽度很宽)。对流行病学和围手术期数据进行了分析,并通过单变量分析和 Kaplan-Meier 图来研究无复发生存率和总生存率。淋巴结阳性(HR 2.50,95% CI 1.11-5.61,p=0.027)和非解剖切除(HR 2.06,95% CI 1.13-3.75,p=0.019)与总生存率较低显著相关。在无复发生存率方面,V2血管侵犯是唯一与较差的无复发生存率显著相关的风险因素(HR 8.83,95% CI 0.85-2.83,P=0.005)。非解剖性切除、淋巴结和血管侵犯均对肿瘤预后有显著影响。
{"title":"The significance of resection margins on R0 results in intrahepatic cholangiocarcinoma","authors":"B.O. Stüben ,&nbsp;S. Ahmadi ,&nbsp;F.H. Saner ,&nbsp;J. Li ,&nbsp;J.P. Neuhaus ,&nbsp;J.W. Treckmann ,&nbsp;D.P. Hoyer","doi":"10.1016/j.suronc.2024.102058","DOIUrl":"https://doi.org/10.1016/j.suronc.2024.102058","url":null,"abstract":"<div><h3>Background</h3><p>Intrahepatic cholangiocarcinoma is the second most common primary liver cancer after hepatocellular carcinoma with an increasing incidence worldwide. Surgical resection is still the only potential cure, and survival rates are dismal due to disease relapse after resection and/or metastatic disease. Positive resection margins are associated with recurrence, with conflicting studies regarding the benefits of wide resection margins to reduce recurrence rates.</p></div><div><h3>Methods</h3><p>126 patients with an R0 resection treated with hepatic surgery for intrahepatic cholangiocarcinoma at the Surgical Department at the Medical University Centre Essen, Germany were identified in a database and retrospectively analysed. Patients were grouped into three groups according to margin width, &lt;1 mm (very narrow margin width) 1–5 mm (narrow margin width) and &gt;5 mm (wide margin width). Epidemiological as well as perioperative data was analysed, and a univariate analysis as well as Kaplan-Meier plots carried out to investigate recurrence-free and overall survival.</p></div><div><h3>Results</h3><p>Wider resection margins did not lead to better recurrence-free survival.</p><p>A wider resection margin &gt;5 mm was not significantly associated with improved overall survival.</p><p>Positive lymph nodes (HR 2.50, 95% CI 1.11–5.61, <strong>p=0.027</strong>) and non-anatomic resections (HR 2.06, 95% CI 1.13–3.75, <strong>p=0.019</strong>) are significantly associated with poorer overall survival. Regarding recurrence-free survival, V2 vascular invasion was the only risk factor statistically significantly associated with poorer recurrence-free survival (HR 8.83, 95% CI 0.85–2.83, <strong>p=0.005</strong>).</p></div><div><h3>Conclusion</h3><p>Resection margins did not have a significant impact on disease free survival or overall survival following hepatic resection for intrahepatic cholangiocarcinoma. Non-anatomical resections, lymph node and vascular invasion all significantly impacted oncological outcomes.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"53 ","pages":"Article 102058"},"PeriodicalIF":2.3,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960740424000264/pdfft?md5=cf9f9d940081f2a63e68394242a57f12&pid=1-s2.0-S0960740424000264-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140016062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interpectoral nerve blocks may lower postoperative narcotic use after mastectomy 胸大肌间神经阻滞可降低乳房切除术后麻醉剂的使用量
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-16 DOI: 10.1016/j.suronc.2024.102055
Ricardo J. Bello , Benjamin A. Palleiko , Kara Kennedy, Lauren Cournoyer, Anne C. Larkin, Kate H. Dinh, Jennifer LaFemina

Background

Pain management following mastectomy is a significant challenge often requiring opioids. Nonopioid pain management utilizing nerve blocks has been shown in other fields to reduce postoperative opioid use and may be effective for postoperative pain in mastectomy patients. The primary purpose of this study was to compare postoperative opioid use, measured in morphine milligram equivalents (MME), between mastectomy patients who underwent interpectoral nerve block (IPNB) and a historical control group. Secondary outcomes included length of stay (LOS) and postoperative pain scores.

Methods

This is a single-center, retrospective cohort study. The charts of women who underwent mastectomy for cancer without immediate reconstruction from 10/2017–12/2019 were reviewed. Wilcoxon rank sum test was used for unadjusted analysis and multiple linear regression for adjusted analysis.

Results

There were 105 patients included in this study, of which 37 (35%) underwent IPNB. In unadjusted analysis, median MME use was significantly lower in patients that received IPNB compared to the control group (IPNB = 5, controls = 17, p = 0.03). Patients that received IPNB had an observed reduction in LOS and postoperative pain, though these results failed to reach statistical significance. There were no IPNB-related complications.

Conclusions

IPNB may be an effective strategy to decrease postoperative opioid use in mastectomy patients. Larger, prospective studies are needed to further investigate the effectiveness of IPNB.

背景乳房切除术后的疼痛治疗是一项重大挑战,通常需要使用阿片类药物。其他领域的研究表明,利用神经阻滞进行非阿片类药物止痛可减少术后阿片类药物的使用,对乳腺切除术患者的术后疼痛可能有效。本研究的主要目的是比较接受乳头间神经阻滞(IPNB)的乳腺切除术患者与历史对照组的术后阿片类药物用量(以吗啡毫克当量(MME)计)。次要结果包括住院时间(LOS)和术后疼痛评分。研究回顾了2017年10月至2019年12月期间因癌症接受乳房切除术但未立即进行重建的女性病历。结果本研究共纳入 105 例患者,其中 37 例(35%)接受了 IPNB。在未经调整的分析中,与对照组相比,接受 IPNB 的患者 MME 使用量中位数明显降低(IPNB = 5,对照组 = 17,P = 0.03)。据观察,接受 IPNB 治疗的患者的住院时间和术后疼痛均有所缩短,但这些结果均未达到统计学意义。结论IPNB可能是减少乳房切除术患者术后阿片类药物使用的有效策略。需要进行更大规模的前瞻性研究来进一步探讨 IPNB 的有效性。
{"title":"Interpectoral nerve blocks may lower postoperative narcotic use after mastectomy","authors":"Ricardo J. Bello ,&nbsp;Benjamin A. Palleiko ,&nbsp;Kara Kennedy,&nbsp;Lauren Cournoyer,&nbsp;Anne C. Larkin,&nbsp;Kate H. Dinh,&nbsp;Jennifer LaFemina","doi":"10.1016/j.suronc.2024.102055","DOIUrl":"10.1016/j.suronc.2024.102055","url":null,"abstract":"<div><h3>Background</h3><p>Pain management following mastectomy is a significant challenge often requiring opioids. Nonopioid pain management utilizing nerve blocks has been shown in other fields to reduce postoperative opioid use and may be effective for postoperative pain in mastectomy patients. The primary purpose of this study was to compare postoperative opioid use, measured in morphine milligram equivalents (MME), between mastectomy patients who underwent interpectoral nerve block (IPNB) and a historical control group. Secondary outcomes included length of stay (LOS) and postoperative pain scores.</p></div><div><h3>Methods</h3><p>This is a single-center, retrospective cohort study. The charts of women who underwent mastectomy for cancer without immediate reconstruction from 10/2017–12/2019 were reviewed. Wilcoxon rank sum test was used for unadjusted analysis and multiple linear regression for adjusted analysis.</p></div><div><h3>Results</h3><p>There were 105 patients included in this study, of which 37 (35%) underwent IPNB. In unadjusted analysis, median MME use was significantly lower in patients that received IPNB compared to the control group (IPNB = 5, controls = 17, <em>p</em> = 0.03). Patients that received IPNB had an observed reduction in LOS and postoperative pain, though these results failed to reach statistical significance. There were no IPNB-related complications.</p></div><div><h3>Conclusions</h3><p>IPNB may be an effective strategy to decrease postoperative opioid use in mastectomy patients. Larger, prospective studies are needed to further investigate the effectiveness of IPNB.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"53 ","pages":"Article 102055"},"PeriodicalIF":2.3,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139921162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scarless totally implantable venous access port (TIVAP) implantation: Surgical technique, preliminary results, learning curve, and patients-reported outcome in 125 breast cancer patients 无疤痕全植入式静脉通路端口(TIVAP)植入术:125 例乳腺癌患者的手术技术、初步结果、学习曲线和患者报告结果
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-14 DOI: 10.1016/j.suronc.2024.102048
Yi-Lin Chang , Chayanee Sae-lim , Shih-Lung Lin , Hung-Wen Lai , Hsin-I Huang , Yuan-Chieh Lai , Shou-Tung Chen , Dar-Ren Chen

Background

Minimal-access (endoscopic or robotic-assisted) breast surgery has been increasingly performed and shown better cosmetic results. However, location of totally implantable venous access port (TIVAP) for systemic treatment at anterior chest may compromise its aesthetic benefits. Therefore, we proposed a new scarless technique for TIVAP implantation, and reported the preliminary results, learning curve, and patients-surveyed outcome.

Methods

Surgical technique of the new “scarless” TIVAP implantation was proposed. Patients receiving this procedure in a single institution were included. The preliminary results of the scarless TIVAP implantation, learning curve, and patient-reported outcome were analyzed and reported.

Results

A total of 125 breast cancer patients received scarless TIVAP procedures were enrolled. The primary success rate of the scarless TIVAP implantation was 100%. Mean operative time was 46 ± 14 min. Mean amount of blood loss was 8.5 ± 3.2 ml. The cumulative sum plot showed operation time significantly decreased after 24th cases. In the initial learning phase, the mean operative time was 55 ± 17 min, and decreased to 43 ± 12 min in the later mature phase (P = 0.003). There were 5 (4%) complications detected, which included 1 (0.8%) seroma formation, 2 (1.6%) revisions, and 2 (1.6%) unplanned explantations. From patients-evaluated questionnaires, more than 90% of responders were satisfied with aesthetic results, experience during surgery, and application of scarless TIVAP for systemic therapy.

Conclusions

The scarless TIVAP implantation is a safe & reliable procedure with high patients-reported aesthetic satisfaction, and could be an alternative TIVAP procedure for patients requiring chemotherapy and desiring a less noticeable scar.

背景最小入路(内窥镜或机器人辅助)乳房手术已越来越多地开展,并显示出更好的美容效果。然而,用于系统治疗的全植入式静脉通路端口(TIVAP)位于前胸,可能会影响其美观效果。因此,我们提出了一种新的无疤痕 TIVAP 植入技术,并报告了初步结果、学习曲线和患者调查结果。方法提出了新的 "无疤痕 "TIVAP植入手术技术,纳入了在一家医疗机构接受该手术的患者。分析并报告了无疤痕 TIVAP 植入术的初步结果、学习曲线和患者报告的结果。结果共纳入了 125 名接受无疤痕 TIVAP 手术的乳腺癌患者。无痕 TIVAP 植入术的主要成功率为 100%。平均手术时间为 46 ± 14 分钟。平均失血量为 8.5 ± 3.2 毫升。累积总和图显示,手术时间在第24例后明显缩短。在最初的学习阶段,平均手术时间为 55 ± 17 分钟,而在后来的成熟阶段,平均手术时间缩短为 43 ± 12 分钟(P = 0.003)。共发现 5 例(4%)并发症,包括 1 例(0.8%)血清肿形成、2 例(1.6%)翻修和 2 例(1.6%)计划外切除。结论无疤痕 TIVAP 植入术是一种安全可靠的手术,患者对其美学满意度很高,可以作为需要化疗且希望疤痕不明显的患者的替代 TIVAP 手术。
{"title":"Scarless totally implantable venous access port (TIVAP) implantation: Surgical technique, preliminary results, learning curve, and patients-reported outcome in 125 breast cancer patients","authors":"Yi-Lin Chang ,&nbsp;Chayanee Sae-lim ,&nbsp;Shih-Lung Lin ,&nbsp;Hung-Wen Lai ,&nbsp;Hsin-I Huang ,&nbsp;Yuan-Chieh Lai ,&nbsp;Shou-Tung Chen ,&nbsp;Dar-Ren Chen","doi":"10.1016/j.suronc.2024.102048","DOIUrl":"10.1016/j.suronc.2024.102048","url":null,"abstract":"<div><h3>Background</h3><p>Minimal-access (endoscopic or robotic-assisted) breast surgery has been increasingly performed and shown better cosmetic results. However, location of totally implantable venous access port (TIVAP) for systemic treatment at anterior chest may compromise its aesthetic benefits. Therefore, we proposed a new scarless technique for TIVAP implantation, and reported the preliminary results, learning curve, and patients-surveyed outcome.</p></div><div><h3>Methods</h3><p>Surgical technique of the new “scarless” TIVAP implantation was proposed. Patients receiving this procedure in a single institution were included. The preliminary results of the scarless TIVAP implantation, learning curve, and patient-reported outcome were analyzed and reported.</p></div><div><h3>Results</h3><p>A total of 125 breast cancer patients received scarless TIVAP procedures were enrolled. The primary success rate of the scarless TIVAP implantation was 100%. Mean operative time was 46 ± 14 min. Mean amount of blood loss was 8.5 ± 3.2 ml. The cumulative sum plot showed operation time significantly decreased after 24th cases. In the initial learning phase, the mean operative time was 55 ± 17 min, and decreased to 43 ± 12 min in the later mature phase (P = 0.003). There were 5 (4%) complications detected, which included 1 (0.8%) seroma formation, 2 (1.6%) revisions, and 2 (1.6%) unplanned explantations. From patients-evaluated questionnaires, more than 90% of responders were satisfied with aesthetic results, experience during surgery, and application of scarless TIVAP for systemic therapy.</p></div><div><h3>Conclusions</h3><p>The scarless TIVAP implantation is a safe &amp; reliable procedure with high patients-reported aesthetic satisfaction, and could be an alternative TIVAP procedure for patients requiring chemotherapy and desiring a less noticeable scar.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"53 ","pages":"Article 102048"},"PeriodicalIF":2.3,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960740424000161/pdfft?md5=504fe3ac73f8b977bf4fd5ef7f153cb5&pid=1-s2.0-S0960740424000161-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139816849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy and age: A propensity score matched study 肾部分切除术与根治性肾切除术以及年龄对转移性肾细胞癌其他原因死亡率的影响:倾向评分匹配研究
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-13 DOI: 10.1016/j.suronc.2024.102047
Carolin Siech , Reha-Baris Incesu , Simone Morra , Lukas Scheipner , Andrea Baudo , Letizia Maria Ippolita Jannello , Mario de Angelis , Jordan A. Goyal , Zhe Tian , Fred Saad , Shahrokh F. Shariat , Derya Tilki , Nicola Longo , Luca Carmignani , Ottavio de Cobelli , Sascha Ahyai , Alberto Briganti , Philipp Mandel , Luis A. Kluth , Felix K.H. Chun , Pierre I. Karakiewicz

Introduction

It is unknown whether the benefit from partial nephrectomy regarding lower other-cause mortality is applicable to older patients with metastatic renal cell carcinoma.

Materials and methods

Using Surveillance Epidemiology and End Results database, patients with metastatic renal cell carcinoma, undergoing partial or radical nephrectomy, were stratified according to age (<60, 60–69, and ≥70 years). After propensity score matching, Kaplan-Meier survival analyses and multivariable Cox regression models were used.

Results

Of 2,390 patients with metastatic renal cell carcinoma, 885 (37%) were aged <60 years, and 90 (10%) underwent partial nephrectomy; 824 (34%) were aged 60–69 years, and 61 (7%) underwent partial nephrectomy; and 681 (29%) were aged ≥70 years, and 64 (9%) underwent partial nephrectomy. After propensity score matching, in patients aged <60 years, partial nephrectomy was associated with lower other-cause mortality (hazard ratio 0.22; p = 0.02); in patients aged 60–69 years, partial nephrectomy was associated with lower other-cause mortality (hazard ratio 0.38; p = 0.03); but not in patients aged ≥70 years.

Discussion

In metastatic renal cell carcinoma, partial nephrectomy is associated with lower other-cause mortality in patients aged <60 years and in patients aged 60–69 years, but not in patients aged ≥70 years. In consequence, consideration of partial nephrectomy might be of great value in younger metastatic renal cell carcinoma patients.

材料和方法利用监测流行病学和最终结果数据库,对接受肾部分切除术或根治性肾切除术的转移性肾细胞癌患者按年龄进行分层(60岁、60-69岁和≥70岁)。经过倾向评分匹配后,采用卡普兰-梅耶生存分析和多变量考克斯回归模型。结果 在2390名转移性肾细胞癌患者中,885人(37%)年龄为60岁,90人(10%)接受了肾部分切除术;824人(34%)年龄为60-69岁,61人(7%)接受了肾部分切除术;681人(29%)年龄≥70岁,64人(9%)接受了肾部分切除术。经过倾向评分匹配后,在<60岁的患者中,肾部分切除术与较低的其他原因死亡率相关(危险比为0.22;P = 0.02);在60-69岁的患者中,肾部分切除术与较低的其他原因死亡率相关(危险比为0.讨论在转移性肾细胞癌患者中,肾部分切除术与降低60岁和60-69岁患者的其他原因死亡率有关,但与降低≥70岁患者的其他原因死亡率无关。因此,考虑对年轻的转移性肾细胞癌患者进行肾部分切除术可能具有重要价值。
{"title":"Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy and age: A propensity score matched study","authors":"Carolin Siech ,&nbsp;Reha-Baris Incesu ,&nbsp;Simone Morra ,&nbsp;Lukas Scheipner ,&nbsp;Andrea Baudo ,&nbsp;Letizia Maria Ippolita Jannello ,&nbsp;Mario de Angelis ,&nbsp;Jordan A. Goyal ,&nbsp;Zhe Tian ,&nbsp;Fred Saad ,&nbsp;Shahrokh F. Shariat ,&nbsp;Derya Tilki ,&nbsp;Nicola Longo ,&nbsp;Luca Carmignani ,&nbsp;Ottavio de Cobelli ,&nbsp;Sascha Ahyai ,&nbsp;Alberto Briganti ,&nbsp;Philipp Mandel ,&nbsp;Luis A. Kluth ,&nbsp;Felix K.H. Chun ,&nbsp;Pierre I. Karakiewicz","doi":"10.1016/j.suronc.2024.102047","DOIUrl":"https://doi.org/10.1016/j.suronc.2024.102047","url":null,"abstract":"<div><h3>Introduction</h3><p>It is unknown whether the benefit from partial nephrectomy regarding lower other-cause mortality is applicable to older patients with metastatic renal cell carcinoma.</p></div><div><h3>Materials and methods</h3><p>Using Surveillance Epidemiology and End Results database, patients with metastatic renal cell carcinoma, undergoing partial or radical nephrectomy, were stratified according to age (&lt;60, 60–69, and ≥70 years). After propensity score matching, Kaplan-Meier survival analyses and multivariable Cox regression models were used.</p></div><div><h3>Results</h3><p>Of 2,390 patients with metastatic renal cell carcinoma, 885 (37%) were aged &lt;60 years, and 90 (10%) underwent partial nephrectomy; 824 (34%) were aged 60–69 years, and 61 (7%) underwent partial nephrectomy; and 681 (29%) were aged ≥70 years, and 64 (9%) underwent partial nephrectomy. After propensity score matching, in patients aged &lt;60 years, partial nephrectomy was associated with lower other-cause mortality (hazard ratio 0.22; p = 0.02); in patients aged 60–69 years, partial nephrectomy was associated with lower other-cause mortality (hazard ratio 0.38; p = 0.03); but not in patients aged ≥70 years.</p></div><div><h3>Discussion</h3><p>In metastatic renal cell carcinoma, partial nephrectomy is associated with lower other-cause mortality in patients aged &lt;60 years and in patients aged 60–69 years, but not in patients aged ≥70 years. In consequence, consideration of partial nephrectomy might be of great value in younger metastatic renal cell carcinoma patients.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"53 ","pages":"Article 102047"},"PeriodicalIF":2.3,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S096074042400015X/pdfft?md5=5b14dad3f6316ce0b2ef86b2584b4e7b&pid=1-s2.0-S096074042400015X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139737762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of methylene blue in colorectal cancer: Systematic review and meta-analysis study 亚甲基蓝对结直肠癌的影响:系统回顾和荟萃分析研究
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-09 DOI: 10.1016/j.suronc.2024.102046
Alexandre Carvalho , Nuno Gonçalves , Pedro Teixeira , André Goulart , Pedro Leão

Purpose

In patients with colorectal cancer (CRC), the most important factor to decide the need of adjuvant chemotherapy is the histological lymph node (LN) evaluation. Our work aimed to give a broad view over the use of methylene blue and its consequences in the number of lymph node harvest.

Methods

PUBMED, WEB OF SCIENCE and EMBASE databases were consulted, retrieving clinical trials, which mentioned the used of intra-arterial methylene blue in patients with colorectal cancer.

Results

Eighteen clinical trials analyzing the use of intra-arterial methylene blue in specimens of colorectal cancer were selected. The articles show a statistical difference between the use of methylene blue and the classical dissection in both variable at study. The results of the statistical analysis of the lymph node harvest variable demonstrate a significant statistical difference between the group that received methylene blue injection and the group that underwent conventional dissection. There is a significant statistical difference between the experimental and control groups for the ideal lymph node harvest (lymph node harvest count greater than 12).

Conclusion

The use of intra-arterial methylene blue revealed a high potential for the quantification of lymph nodes, considering the increase of lymph node harvest and the higher percentage of cases with more than 12 lymph nodes count, albeit the high heterogeneity between the studies in terms of reported results. Future investigations with controlled double blinded studies obtaining better categorized results should be conducted in order to better evaluate this technique and compare it to the current paradigm.

目的 在结直肠癌(CRC)患者中,决定是否需要辅助化疗的最重要因素是组织学淋巴结(LN)评估。我们的工作旨在对亚甲蓝的使用及其对淋巴结摘除数量的影响进行广泛的研究。方法查阅了PUBMED、WEB OF SCIENCE和EMBASE数据库,检索了提及在结直肠癌患者中使用动脉内亚甲蓝的临床试验。这些文章显示,在研究的两个变量中,使用亚甲蓝和传统解剖方法之间存在统计学差异。淋巴结摘除变量的统计分析结果显示,接受亚甲蓝注射的组别与接受传统切除术的组别之间存在显著的统计学差异。尽管各研究报告的结果存在很大的异质性,但考虑到淋巴结收获量的增加以及淋巴结数量超过 12 个的病例比例较高,使用动脉内亚甲蓝对淋巴结的量化具有很大的潜力。今后应进行双盲对照研究,以获得更好的分类结果,从而更好地评估这项技术,并将其与当前的范例进行比较。
{"title":"The impact of methylene blue in colorectal cancer: Systematic review and meta-analysis study","authors":"Alexandre Carvalho ,&nbsp;Nuno Gonçalves ,&nbsp;Pedro Teixeira ,&nbsp;André Goulart ,&nbsp;Pedro Leão","doi":"10.1016/j.suronc.2024.102046","DOIUrl":"10.1016/j.suronc.2024.102046","url":null,"abstract":"<div><h3>Purpose</h3><p>In patients with colorectal cancer (CRC), the most important factor to decide the need of adjuvant chemotherapy is the histological lymph node (LN) evaluation. Our work aimed to give a broad view over the use of methylene blue and its consequences in the number of lymph node harvest.</p></div><div><h3>Methods</h3><p>PUBMED, WEB OF SCIENCE and EMBASE databases were consulted, retrieving clinical trials, which mentioned the used of intra-arterial methylene blue in patients with colorectal cancer.</p></div><div><h3>Results</h3><p>Eighteen clinical trials analyzing the use of intra-arterial methylene blue in specimens of colorectal cancer were selected. The articles show a statistical difference between the use of methylene blue and the classical dissection in both variable at study. The results of the statistical analysis of the lymph node harvest variable demonstrate a significant statistical difference between the group that received methylene blue injection and the group that underwent conventional dissection. There is a significant statistical difference between the experimental and control groups for the ideal lymph node harvest (lymph node harvest count greater than 12).</p></div><div><h3>Conclusion</h3><p>The use of intra-arterial methylene blue revealed a high potential for the quantification of lymph nodes, considering the increase of lymph node harvest and the higher percentage of cases with more than 12 lymph nodes count, albeit the high heterogeneity between the studies in terms of reported results. Future investigations with controlled double blinded studies obtaining better categorized results should be conducted in order to better evaluate this technique and compare it to the current paradigm.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"53 ","pages":"Article 102046"},"PeriodicalIF":2.3,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960740424000148/pdfft?md5=8558b276ae115236ea8419fd5025555b&pid=1-s2.0-S0960740424000148-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139878018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical implications of C-reactive protein–albumin–lymphocyte (CALLY) index in patients with esophageal cancer 食管癌患者的 C 反应蛋白-白蛋白-淋巴细胞(CALLY)指数的临床意义
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-05 DOI: 10.1016/j.suronc.2024.102044
Ruiya Ma , Yoshinaga Okugawa , Tadanobu Shimura , Shinji Yamashita , Yuhki Sato , Chengzeng Yin , Ryo Uratani , Takahito Kitajima , Hiroki Imaoka , Mikio Kawamura , Yuhki Morimoto , Yoshiki Okita , Shigeyuki Yoshiyama , Masaki Ohi , Yuji Toiyama

Purpose

The C-reactive protein–albumin–lymphocyte (CALLY) index is a novel inflammatory nutritional biomarker. This study aimed to investigate the potential clinical significance and oncological prognostic role of the preoperative CALLY index in patients with esophageal cancer.

Methods

We analyzed the preoperative CALLY index in 146 patients with esophageal cancer. The CALLY index and clinicopathological variables were analyzed by the Mann–Whitney U test, and associations between the CALLY index and survival outcomes were analyzed by Kaplan–Meier analysis and log-rank tests. Univariate and multivariate analyses of prognostic variables were conducted using Cox proportional hazards regression.

Results

A lower preoperative CALLY index was significantly correlated with patient age, advanced T stage, presence of lymph node metastasis, neoadjuvant therapy, lymphatic invasion, and advanced stage classification. The preoperative CALLY index decreased significantly in a stage-dependent manner. Patients with esophageal cancer with a low CALLY index had poorer overall survival, disease-free survival than those with a high CALLY index. Multivariate analysis showed that a low CALLY index was an independent prognostic factor for overall survival, disease-free survival and an independent predictor of postoperative surgical site infection.

Conclusions

Preoperative CALLY index is a useful marker to guide the perioperative and postoperative management of patients with esophageal cancer.

目的 C反应蛋白-白蛋白-淋巴细胞(CALLY)指数是一种新型炎症营养生物标志物。本研究旨在探讨食管癌患者术前 CALLY 指数的潜在临床意义和肿瘤预后作用。采用 Mann-Whitney U 检验分析 CALLY 指数和临床病理变量,采用 Kaplan-Meier 分析和对数秩检验分析 CALLY 指数和生存结果之间的关系。结果 较低的术前CALLY指数与患者年龄、T期晚期、淋巴结转移、新辅助治疗、淋巴侵犯和晚期分期显著相关。术前CALLY指数的下降与分期有关。CALLY指数低的食管癌患者的总生存期和无病生存期均低于CALLY指数高的患者。多变量分析显示,低 CALLY 指数是总生存率和无病生存率的独立预后因素,也是术后手术部位感染的独立预测因素。
{"title":"Clinical implications of C-reactive protein–albumin–lymphocyte (CALLY) index in patients with esophageal cancer","authors":"Ruiya Ma ,&nbsp;Yoshinaga Okugawa ,&nbsp;Tadanobu Shimura ,&nbsp;Shinji Yamashita ,&nbsp;Yuhki Sato ,&nbsp;Chengzeng Yin ,&nbsp;Ryo Uratani ,&nbsp;Takahito Kitajima ,&nbsp;Hiroki Imaoka ,&nbsp;Mikio Kawamura ,&nbsp;Yuhki Morimoto ,&nbsp;Yoshiki Okita ,&nbsp;Shigeyuki Yoshiyama ,&nbsp;Masaki Ohi ,&nbsp;Yuji Toiyama","doi":"10.1016/j.suronc.2024.102044","DOIUrl":"https://doi.org/10.1016/j.suronc.2024.102044","url":null,"abstract":"<div><h3>Purpose</h3><p>The C-reactive protein–albumin–lymphocyte (CALLY) index is a novel inflammatory nutritional biomarker. This study aimed to investigate the potential clinical significance and oncological prognostic role of the preoperative CALLY index in patients with esophageal cancer.</p></div><div><h3>Methods</h3><p>We analyzed the preoperative CALLY index in 146 patients with esophageal cancer. The CALLY index and clinicopathological variables were analyzed by the Mann–Whitney <em>U</em> test, and associations between the CALLY index and survival outcomes were analyzed by Kaplan–Meier analysis and log-rank tests. Univariate and multivariate analyses of prognostic variables were conducted using Cox proportional hazards regression.</p></div><div><h3>Results</h3><p>A lower preoperative CALLY index was significantly correlated with patient age, advanced T stage, presence of lymph node metastasis, neoadjuvant therapy, lymphatic invasion, and advanced stage classification. The preoperative CALLY index decreased significantly in a stage-dependent manner. Patients with esophageal cancer with a low CALLY index had poorer overall survival, disease-free survival than those with a high CALLY index. Multivariate analysis showed that a low CALLY index was an independent prognostic factor for overall survival, disease-free survival and an independent predictor of postoperative surgical site infection.</p></div><div><h3>Conclusions</h3><p>Preoperative CALLY index is a useful marker to guide the perioperative and postoperative management of patients with esophageal cancer.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"53 ","pages":"Article 102044"},"PeriodicalIF":2.3,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139709230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of low dose superparamagnetic iron oxide tracer for sentinel node biopsy in breast conserving treatment on susceptibility artefacts on magnetic resonance imaging and contrast enhanced mammography 用于保乳治疗前哨节点活检的低剂量超顺磁性氧化铁示踪剂对磁共振成像和对比增强型乳腺 X 射线照相术中易感性伪影的影响
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-05 DOI: 10.1016/j.suronc.2024.102045
Elisabeth R.M. van Haaren , Merel A. Spiekerman van Weezelenburg , James van Bastelaar , Alfred Janssen , Thiemo van Nijnatten , Lee H. Bouwman , Yvonne L.J. Vissers , Marc B.I. Lobbes

Background

Residual particles of superparamagnetic iron oxide (SPIO) tracer, used for sentinel node biopsy, cause susceptibility artefacts on breast Magnetic Resonance Imaging (MRI). We investigated the impact of these artefacts on the imaging quality of MRI and explored whether contrast-enhanced mammography (CEM) could be an alternative in the follow-up of breast cancer patients.

Materials and methods

Data on patients’ characteristics, injection site, presence, size (mm) of artefacts on full-field digital mammography (FFDM)/CEM, MRI after 1 ml SPIO was recorded. Image quality scored by two breast radiologists using a 4-point Likert system: 0: no artefacts 1: good diagnostic quality 2: impaired but still readable 3: hampered clinical assessment. Continuous variables reported as means and standard deviations (SD), categorical variables as count and percentage.

Results

On FFDM/CEM, performed 13 months postoperatively, no iron SPIO particles were detected, with a Likert score of 0. In all MRI (100%) images, executed at 16.6 months after SPIO injection, susceptibility artefacts at the injection sites i.e., retroareolair and lateral quadrant were observed with a mean size of 41.9 ± 9.8 mm (SD) by observer 1, and 44.8 ± 12.5 mm (SD) by observer 2, independent of the injection site. Both observers scored a Likert score of 2: locally impaired on all MRI images and sequences.

Conclusions

Even 1 ml SPIO tracer used for sentinel node procedure impairs the evaluation of breast MRI at the tracer injection site beyond one year of follow-up. No impairment was observed on FFDM/CEM, suggesting that CEM might be a reliable alternative to breast MRI if required.

背景用于前哨节点活检的超顺磁性氧化铁(SPIO)示踪剂残留微粒会在乳腺磁共振成像(MRI)上造成感性伪影。我们研究了这些伪影对核磁共振成像质量的影响,并探讨了造影剂增强乳腺 X 线造影术(CEM)是否可作为乳腺癌患者随访的替代方法。材料和方法记录了患者特征、注射部位、存在情况、1 毫升 SPIO 后全场数字乳腺 X 线造影术(FFDM)/CEM 和核磁共振成像的伪影大小(毫米)等数据。图像质量由两名乳腺放射科医生使用 4 点 Likert 系统进行评分:0:无伪影 1:诊断质量良好 2:有缺陷但仍可读 3:妨碍临床评估。连续变量以平均值和标准差(SD)表示,分类变量以计数和百分比表示。结果在术后 13 个月进行的 FFDM/CEM 检查中,未检测到 SPIO 铁颗粒,Likert 评分为 0、观察者 1 的平均值为 41.9 ± 9.8 毫米(标清),观察者 2 的平均值为 44.8 ± 12.5 毫米(标清),与注射部位无关。结论即使是用于前哨节点手术的 1 毫升 SPIO 示踪剂也会在随访一年后影响示踪剂注射部位的乳腺 MRI 评估。在 FFDM/CEM 上未观察到损害,这表明如果需要,CEM 可能是乳腺 MRI 的可靠替代方法。
{"title":"Impact of low dose superparamagnetic iron oxide tracer for sentinel node biopsy in breast conserving treatment on susceptibility artefacts on magnetic resonance imaging and contrast enhanced mammography","authors":"Elisabeth R.M. van Haaren ,&nbsp;Merel A. Spiekerman van Weezelenburg ,&nbsp;James van Bastelaar ,&nbsp;Alfred Janssen ,&nbsp;Thiemo van Nijnatten ,&nbsp;Lee H. Bouwman ,&nbsp;Yvonne L.J. Vissers ,&nbsp;Marc B.I. Lobbes","doi":"10.1016/j.suronc.2024.102045","DOIUrl":"https://doi.org/10.1016/j.suronc.2024.102045","url":null,"abstract":"<div><h3>Background</h3><p>Residual particles of superparamagnetic iron oxide (SPIO) tracer, used for sentinel node biopsy, cause susceptibility artefacts on breast Magnetic Resonance Imaging (MRI). We investigated the impact of these artefacts on the imaging quality of MRI and explored whether contrast-enhanced mammography (CEM) could be an alternative in the follow-up of breast cancer patients.</p></div><div><h3>Materials and methods</h3><p>Data on patients’ characteristics, injection site, presence, size (mm) of artefacts on full-field digital mammography (FFDM)/CEM, MRI after 1 ml SPIO was recorded. Image quality scored by two breast radiologists using a 4-point Likert system: 0: no artefacts 1: good diagnostic quality 2: impaired but still readable 3: hampered clinical assessment. Continuous variables reported as means and standard deviations (SD), categorical variables as count and percentage.</p></div><div><h3>Results</h3><p>On FFDM/CEM, performed 13 months postoperatively, no iron SPIO particles were detected, with a Likert score of 0. In all MRI (100%) images, executed at 16.6 months after SPIO injection, susceptibility artefacts at the injection sites i.e., retroareolair and lateral quadrant were observed with a mean size of 41.9 ± 9.8 mm (SD) by observer 1, and 44.8 ± 12.5 mm (SD) by observer 2, independent of the injection site. Both observers scored a Likert score of 2: locally impaired on all MRI images and sequences.</p></div><div><h3>Conclusions</h3><p>Even 1 ml SPIO tracer used for sentinel node procedure impairs the evaluation of breast MRI at the tracer injection site beyond one year of follow-up. No impairment was observed on FFDM/CEM, suggesting that CEM might be a reliable alternative to breast MRI if required.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"53 ","pages":"Article 102045"},"PeriodicalIF":2.3,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139699577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteosarcopenia impacts treatment outcomes for Barcelona Cancer Liver Classification stage A hepatocellular carcinoma 骨肉疏松症影响巴塞罗那癌症肝分类 A 期肝细胞癌的治疗效果
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-02 DOI: 10.1016/j.suronc.2024.102043
Kyohei Abe, Kenei Furukawa, Michinori Matsumoto, Yasuro Futagawa, Hironori Shiozaki, Shinji Onda, Koichiro Haruki, Yoshihiro Shirai, Tomoyoshi Okamoto, Toru Ikegami

Aim

To study the effect of preoperative osteosarcopenia (OSP) on the prognosis of treatment (surgery or radiofrequency ablation (RFA)) in patients with Barcelona Cancer Liver Classification stage A hepatocellular carcinoma (BCLC A HCC).

Methods

This study enrolled 102 patients with BCLC A HCC who underwent surgical resection (n = 45) and RFA (n = 57); the patients were divided into two groups: OSP (n = 33) and non-OSP (n = 69). Overall survival (OS) and disease-free survival (DFS) curves for both the groups and treatment methods (surgery and RFA) were generated using the Kaplan–Meier method and compared using the log-rank test. Univariate analyses for OS and DFS were performed using log-rank test. Multivariate analyses were performed for factors that were significant at univariate analysis by Cox proportional hazard model.

Results

Multivariate analysis showed that OSP (HR 2.44; 95 % CI 1.30–4.55; p < 0.01) and treatment (HR 0.57; 95 % CI 0.31–0.99; p = 0.05) were significant independent predictors of DFS; and treatment (HR, 0.30; 95 % CI 0.10–0.85; p = 0.03) was a significant independent predictor of OS in the non-OSP group, in which the OS rate was significantly lower in patients treated with RFA than in those treated by resection (p = 0.01).

Conclusions

OSP is a prognostic factor for BCLC A HCC treatment. Surgical approach was associated with a significantly better prognosis in patients without OSP compared to those who underwent RFA.

目的研究巴塞罗那癌症肝分类 A 期肝细胞癌(BCLC A HCC)患者术前骨质疏松症(OSP)对治疗(手术或射频消融(RFA))预后的影响。方法本研究共纳入 102 例 BCLC A HCC 患者,他们分别接受了手术切除(n = 45)和射频消融(RFA)(n = 57);患者分为两组:OSP组(33人)和非OSP组(69人)。使用 Kaplan-Meier 法生成两组患者和治疗方法(手术和 RFA)的总生存期(OS)和无病生存期(DFS)曲线,并使用对数秩检验进行比较。采用对数秩检验对 OS 和 DFS 进行单变量分析。结果多变量分析显示,OSP(HR 2.44;95 % CI 1.30-4.55;p <;0.01)和治疗(HR 0.57;95 % CI 0.31-0.99;p = 0.05)是 DFS 的重要独立预测因素;治疗(HR,0.30;95 % CI 0.10-0.85;p = 0.03)是非OSP组OS的显著独立预测因子,其中RFA治疗患者的OS率显著低于切除治疗患者(p = 0.01).结论OSP是BCLC A HCC治疗的预后因素。结论OSP是BCLC A型HCC治疗的预后因素,与接受RFA治疗的患者相比,手术治疗与无OSP患者明显较好的预后相关。
{"title":"Osteosarcopenia impacts treatment outcomes for Barcelona Cancer Liver Classification stage A hepatocellular carcinoma","authors":"Kyohei Abe,&nbsp;Kenei Furukawa,&nbsp;Michinori Matsumoto,&nbsp;Yasuro Futagawa,&nbsp;Hironori Shiozaki,&nbsp;Shinji Onda,&nbsp;Koichiro Haruki,&nbsp;Yoshihiro Shirai,&nbsp;Tomoyoshi Okamoto,&nbsp;Toru Ikegami","doi":"10.1016/j.suronc.2024.102043","DOIUrl":"10.1016/j.suronc.2024.102043","url":null,"abstract":"<div><h3>Aim</h3><p>To study the effect of preoperative osteosarcopenia (OSP) on the prognosis of treatment (surgery or radiofrequency ablation (RFA)) in patients with Barcelona Cancer Liver Classification stage A hepatocellular carcinoma (BCLC A HCC).</p></div><div><h3>Methods</h3><p>This study enrolled 102 patients with BCLC A HCC who underwent surgical resection (n = 45) and RFA (n = 57); the patients were divided into two groups: OSP (n = 33) and non-OSP (n = 69). Overall survival (OS) and disease-free survival (DFS) curves for both the groups and treatment methods (surgery and RFA) were generated using the Kaplan–Meier method and compared using the log-rank test. Univariate analyses for OS and DFS were performed using log-rank test. Multivariate analyses were performed for factors that were significant at univariate analysis by Cox proportional hazard model.</p></div><div><h3>Results</h3><p>Multivariate analysis showed that OSP (HR 2.44; 95 % CI 1.30–4.55; p &lt; 0.01) and treatment (HR 0.57; 95 % CI 0.31–0.99; p = 0.05) were significant independent predictors of DFS; and treatment (HR, 0.30; 95 % CI 0.10–0.85; p = 0.03) was a significant independent predictor of OS in the non-OSP group, in which the OS rate was significantly lower in patients treated with RFA than in those treated by resection (p = 0.01).</p></div><div><h3>Conclusions</h3><p>OSP is a prognostic factor for BCLC A HCC treatment. Surgical approach was associated with a significantly better prognosis in patients without OSP compared to those who underwent RFA.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"53 ","pages":"Article 102043"},"PeriodicalIF":2.3,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139661813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Double hepatic vein reconstruction during extended anatomical resection of segment 8 for colorectal liver metastasis 在结直肠肝转移第 8 节段扩大解剖切除术中重建双肝静脉
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-02-01 DOI: 10.1016/j.suronc.2024.102040
Katsuya Sakashita, Shimpei Otsuka, Katsuhiko Uesaka, Teiichi Sugiura

Background

Hepatic vein reconstruction (HVR) is occasionally necessary for resecting hepatic malignancies to ensure surgical margins while preserving remnant liver function [1]. Reports of multiple HVR are rare due to the highly technical demanding procedure and high risk of morbidity [2]. We introduce our procedure of double HVR for metastatic liver tumors invading the right hepatic vein (RHV) and middle hepatic vein (MHV).

Methods

The patient was a 66-year-old man with colorectal liver metastasis in segment 8, invading RHV and MHV. Due to impaired liver function, extended right hemihepatectomy was unsuitable. Thus, extended anatomical resection of segment 8 with double HVR was performed. The liver was completely mobilized and the RHV and MHV were secured. After liver parenchyma dissection, the specimen was connected by RHV and MHV (Fig. 1). The MHV was dissected and reconstructed using a right superficial femoral vein graft while the RHV remained connected [3]. Reconstruction of the MHV was performed on the posterior wall of the proximal side, followed by the anterior wall, using 4-point supporting threads. Anastomosis was performed by the over-and-over suture method. On the distal side, two-point supporting threads were applied. After specimen removal, the RHV was resected and reconstructed in the same manner using a left internal jugular vein graft [4].

Results

The patient was discharged on postoperative day 14 with no signs of liver failure. Computed tomography performed six months after surgery revealed no graft occlusion (Fig. 2).

Conclusion

In appropriately selected patients, this technique may be a useful option for preserving the remnant liver function.

背景肝静脉重建(HVR)有时是切除肝脏恶性肿瘤的必要手段,以确保手术切缘,同时保留残余肝功能(Nakamura 等人,1993 年)[1]。由于手术技术要求高、发病风险大,因此很少有多次 HVR 的报道(Wakabayashi 等人,1998 年)[2]。我们介绍了针对侵犯右肝静脉(RHV)和肝中静脉(MHV)的转移性肝肿瘤的双 HVR 手术。由于肝功能受损,不适合进行扩大右半肝切除术。因此,对第 8 节段进行了扩大解剖切除,并进行了双 HVR。肝脏被完全移动,RHV 和 MHV 被固定。解剖肝实质后,标本由 RHV 和 MHV 连接(图 1)。用右股浅静脉移植物解剖并重建 MHV,同时保持 RHV 的连接(Matsuki 等人,2021 年)[3]。使用四点支撑线在近侧后壁重建 MHV,然后重建前壁。吻合采用套叠缝合法。远端则使用两点支撑线。标本移除后,切除 RHV,并以同样的方式使用左颈内静脉移植进行重建(Hirono 等人,2014 年)[4]。结果患者术后第 14 天出院,无肝功能衰竭迹象。术后 6 个月进行的计算机断层扫描显示没有移植物闭塞(图 2)。
{"title":"Double hepatic vein reconstruction during extended anatomical resection of segment 8 for colorectal liver metastasis","authors":"Katsuya Sakashita,&nbsp;Shimpei Otsuka,&nbsp;Katsuhiko Uesaka,&nbsp;Teiichi Sugiura","doi":"10.1016/j.suronc.2024.102040","DOIUrl":"10.1016/j.suronc.2024.102040","url":null,"abstract":"<div><h3>Background</h3><p>Hepatic vein reconstruction (HVR) is occasionally necessary for resecting hepatic malignancies to ensure surgical margins while preserving remnant liver function [<span>1</span>]. Reports of multiple HVR are rare due to the highly technical demanding procedure and high risk of morbidity [<span>2</span>]. We introduce our procedure of double HVR for metastatic liver tumors invading the right hepatic vein (RHV) and middle hepatic vein (MHV).</p></div><div><h3>Methods</h3><p>The patient was a 66-year-old man with colorectal liver metastasis in segment 8, invading RHV and MHV. Due to impaired liver function, extended right hemihepatectomy was unsuitable. Thus, extended anatomical resection of segment 8 with double HVR was performed. The liver was completely mobilized and the RHV and MHV were secured. After liver parenchyma dissection, the specimen was connected by RHV and MHV (<span>Fig. 1</span>). The MHV was dissected and reconstructed using a right superficial femoral vein graft while the RHV remained connected [<span>3</span>]. Reconstruction of the MHV was performed on the posterior wall of the proximal side, followed by the anterior wall, using 4-point supporting threads. Anastomosis was performed by the over-and-over suture method. On the distal side, two-point supporting threads were applied. After specimen removal, the RHV was resected and reconstructed in the same manner using a left internal jugular vein graft [<span>4</span>].</p></div><div><h3>Results</h3><p>The patient was discharged on postoperative day 14 with no signs of liver failure. Computed tomography performed six months after surgery revealed no graft occlusion (<span>Fig. 2</span>).</p></div><div><h3>Conclusion</h3><p>In appropriately selected patients, this technique may be a useful option for preserving the remnant liver function.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"52 ","pages":"Article 102040"},"PeriodicalIF":2.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139661811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Surgical Oncology-Oxford
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1